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body weight and were more frequently men. At 12 months, a bleeding
complication occurred in 40% of patients regardless of its severity or treat-
ment prescribed. Major bleedings (BARC 3) were significantly lower with
prasugrel than clopidogrel (1% versus 6%, p=0.001). Minimal bleedings
(BARC 1) were more frequent in clopidogrel group than prasugrel group
(respectively 27% and 18%; p=0.05). However BARC 2 bleedings occurred
more often in prasugrel group (14% versus 6%, p=0.01) (figure). Subcuta-
neous and gastrointestinal haemorraghes were the most frequent. Over one-
year, the rate of cessation was 18% in the prasugrel group and only 10% in
the clopidogrel group (p=0.04). Respectively for prasugrel and clopidogrel,
rates of recommend discontinuation were 10% and 4% (p=0.02) and of dis-
ruption were 8% and 5% (p=0.3). Despite more frequent discontinuation, mor-
tality remains very low in the prasugrel group (0.5% versus 7%, p=0.0003).
Conclusion: In real-world, in a low bleeding risk population, the rate of
major bleedings with prasugrel at 12 months was low but nuisance bleedings
were frequent with significant impact on premature cessation 
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Purpose: Dual antiplatelet therapy with a P2Y12 inhibitor is mandatory in
acute coronary syndromes (ACS) undergoing angioplasty. New antiplatelet
drugs prasugrel and ticagrelor offer more efficient inhibition compared to
clopidogrel. Under P2Y12 inhibitor, platelet reactivity (PR) assessment can
predict ischemic and bleeding events. The aim of our study was to compare
PR of P2Y12 inhibitors in a real-world setting. 
Methods: PR was prospectively assesed in consecutive patients with
recurent ACS or undergoing high risk angioplasty. PR was measured 24h after
last intake of clopidogrel (C) and prasugrel (P) and 12h for ticagrelor (T) by
flow cytometry measured vasodilatator-stimulated phosphoprotein platelet
reactivity index (VASP-PRI) and light transmission agregometry with ADP
20μM (LTA-ADP). High Platelet Reactivity (HPR) was defined as VASP-
PRI>50% or LTA-ADP>65% (thresholds previously linked to clinical events).
Low Platelet Reactivity (LPR) was defined as VASP-PRI<16% or LTA-
ADP<40%. 
Results: 619 patients treated with aspirin and C (n=269), P (n=241) or T
(n=109) were included from 01/2011 to 07/2013. Mean age was 62±13y.o.
81% were men and 65% STEMI. HPR was more frequent with C compared
to P and T and significantly more frequent with P compared to T (Table). At
the opposite, LPR was significantly more frequent in patients treated with T.
Clinical and biological characteristics were similar between patients on P and
those on T, except for hypertension, BMI and prior history of STEMI. In mul-
tivariate analysis, the significant predictor of HPR with VASP was P
(OR=0.13-CI [0.08-0.22]) or T (OR=0.01-[0.01-0.09]). The significant pre-
dictor of LPR with VASP was T (OR=3.37-[2.09-5.44]). 
Conclusion: This observational biological prospective study confirms a
more potent platelet inhibition of the new P2Y12 compared to clopidogrel,
mainly T. The very high rate of LPR found with T does not match with the
bleeding risk found in the PLATO trial.
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Aims: Fondaparinux is an alternative to low molecular weight heparin
(LMWH) for non-ST-elevation myocardial infarction (NSTEMI) with levels
of recommendation that differ according to guidelines. The aim of this study
was to assess one-year survival in real world practice in NSTEMI patients par-
ticipating in the French Registry of ST-elevation and non-ST-elevation Myo-
cardial Infarction (FAST-MI) 2010 according to the use of fondaparinux, in
comparison with patients receiving enoxaparin.
Methods and Results: FAST-MI 2010 is a nationwide French registry that
included 4,169 patients with acute myocardial infarction (AMI) at the end of
2010 in 213 centres (76% of active centres in France). Of those, 1,734 had
NSTEMI, of whom 240 received fondaparinux and 1,027 enoxaparin. Patients
receiving enoxaparin vs. fondaparinux were similar for many characteristics;
especially with a similar GRACE (Global Registry of Acute Coronary Events)
score (133±36 vs. 134±38). Invasive strategy was used in 69% in both groups.
In-hospital bleeding was similar with both anticoagulant strategies and one-
year survival was 94.6% vs. 91.7% respectively. Using fully adjusted Cox
multivariate analysis, the use of fondaparinux was not associated with a
reduced risk of death (hazard ratio [HR]: 1.35; 95% confidence interval [CI]:
0.70-2.51). After propensity score matching (207 patients per group), one-year
survival was similar with both strategies.
Conclusions: In this real-world cohort of NSTEMI patients, most of whom
were managed invasively, there was no evidence that fondaparinux was supe-
rior to enoxaparin as regards bleeding events or one-year mortality. (FAST-MI
2010; NCT01237418)
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Background: Antithrombotic therapy and invasive revascularization play
an important role in reducing ischemic events in Acute Coronary Syndromes
(ACS), but paradoxically, increase the risk of bleeding complications (BC).
Abstract 0098 – Figure: 12 months bleedings classification
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We sought to determine the prevalence, predictors and prognostic value of BC
in patients (P) admitted with ACS. 
Methods: Retrospective study including 1345 P with ACS consecutively
admitted to a coronary care unit over 3 years and during a minimal 6 months
follow-up. BC were defined according to TIMI or GUSTO classification sys-
tems. BC classified as minimal or mild were excluded. 
Results: During hospitalization, 53 (3,9%) P developed BC and 1,7% had
severe BC. P situação BC were older (70±12 vs 64±13y;p=0.002) and more
often had chronic renal failure (15,1% vs 4,1%; p=0.002). At admission, they
had more often signs of heart failure (HF) (49,1% vs 20,4%; p<0.001). They
had higher mean levels of creatinine (p <0.001), cystatin C (p=0.023), type B
natriuretic peptide (p<0.001) and red blood cell distribution width (RDW)
(p=0.029), and lower mean levels of glomerular filtration rate (GFR), esti-
mated either by MDRD equation (p<0.001) or Cockcroft-Gault equation
(p<0.001). The echocardiographic evaluation showed that they had more often
moderate to severe left ventricular systolic dysfunction (46,2% vs 31,9%;
p=0.029). They were less likely to undergo invasive stratification (7,6% vs
1,6%; p<0.001), and when done, they had more often left main (22,6% vs
10,3%; p=0.028) and multivessel disease (66,0% vs 44,6%; p=0.002). After
multivariate analysis, HF at admission, lower GFR and higher RDW persisted
as independent predictors of BC. BC were an independent predictor of mor-
tality (OR 4,20; CI 95%; 2,6-6,2; p<0,001) and in-hospital MACE (OR 6,8;
CI 95%; 1,3-3,2; p<0,001), but this trend didn’t persisted in follow-up. 
Conclusion: BC predict a poor in-hospital outcome. Ischemic risk stratifi-
cation plays a central role in optimal treatment approach and should be com-
plemented by bleeding risk assessment. In this study, the presence at
admission of HF, renal dysfunction and high RDW values were independent
predictors of BC.
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Background: Limited data are available in elderly patients admitted for acute
coronary syndromes (ACS). The purpose of this study is to assess the benefi-
cial impact of aggressive treatment strategy (i.e. coronary angiogram and
revascularization) on outcome in elderly patients.
Method: Among 1702 patients admitted for ACS, 294 patients were
≥80 years old. ACS was defined as chest pain associated with either troponin
rise or new change in ST segment or T wave. Patients with STEMI were
excluded and 235 patients (85±3 years old, 125 men) were analyzed. We
compared outcome (death and emergency readmission) according to treatment
strategy (conservative or invasive)
Results: Coronary angiography was performed in 146 patients while 88
received medical treatment alone. Patients with angiography performed were
younger (84.5±3.2 years vs. 85.6±3.9 years) but had similar event risk
(GRACE score 174±26 vs. 179±33). During follow up (median=498 days),
one year mortality and emergency readmission was similar regardless the
decision to perform angiogram (41.2% vs. 43.6%, p=0.7) but in hospital stay
was longer when angiogram was performed (4.1±3.7 vs. 2.9±2.8, p=0.01).
Among the 146 patients who underwent angiography, revascularization was
performed in 98. Age did not influence revascularization but Grace score did
(177±26 vs. 167±30). Importantly, only patients with Left main (LM) or pro-
ximal LAD disease benefited from revascularization (1-year free event sur-
vival 26% vs. 79%, p=0.0003) whereas patients without did not (39% vs.
35%, p=0.7). Kaplan Meier analysis of outcome during follow up confirmed
that patients with non revascularized LM or proximal LAD disease had worth
outcome (LogRank p=0.009)
Conclusion: Invasive management of ACS in elderly patients improves
survival in patients with LM or proximal LAD disease. In other patients, it
only prolongs in-hospital stay. Upstream stratification may be useful to iden-
tify patients with suspected LM or proximal LAD disease.
0051
Acute coronary syndrome and diabetes mellitus in elderly patients
Laila Bouzouba (1), R.Habbal (1), Fabien De Poli (2), Philippe Couppie (2),
Pierre Leddet (2), Michel Hanssen (2)
(1) CHU Ibn Rochd, Cardiologie, Casablanca, Maroc – (2) CH Hague-
nau, USIC, Haguenau, France
Coronary heart disease is the first cause of morbidity and mortality in dia-
betic patients. Its incidence in elderly patients increases with the increase of
their life expectancy. The aim of our study was to evaluate the characteristics
and the management of elderly patients with diabetes and compared this with
non- diabetics patients.
This is a comparative retrospective study of 204 elderly patients
(>75 years) admitted for ACSin haguenau Hospital center in France, between
August 2012 and August 2013. We compared 63 elderly patients diabetics
(GI), with 141 elderly patients non-diabetic (GII)
The mode age: 80years (GI), 82years (GII). A male predominance noted in
the both groups. More risk factors in (GI): hypertension (p=0.002), dyslipi-
demia (p=0.034), while (GII) is more smoker (p=0.003). More comorbidities
for (GI), especially high frequency of renal failure (p<0.001). Predominance
of atypical pain in both groups. NSTEMI was predominant in the both groups.
At coronary angiography, three-vessel involvement was more frequent in (GI).
Percutaneous coronary intervention (PCI) is less used in theGI (62.7%) toGII
(69.5%). Hospital complications were higher in diabetics particulary: renal
failure (p=0.04). Evolution at6and12month ago shows a more predominance
of complications in diabetics. The quality of life of nondiabetic is better than
in diabetics. On the other hand, the quality of life of the diabetics after PCI
was better to conventional therapy. Elderly diabetic patients are very high car-
diovascular risk, characterized by the severity of coronary artery disease. Dia-
betics are treated less aggressively than non-diabetics yet that diabetics quality
of life improves better with angioplasty in comparison with the conventional
treatment.
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Acute coronary syndrome in the elderly patients is a particular clinical
entity characterized by increased incidence. Medical advances and improve-
ment of the conditions of life acquires of the elderly person the progression of
their autonomy. Our aim is to evaluate the quality of life of elderly patients
after ACS treated by angioplasty.
We had collected 141 elderly patients (>75 ans) (mean age:80.6± 4.03 years
old) admitted for NSTEMI in Haguenau hospital center in France, between
august 2012 and august  2013. 58.2% had percutaneous coronary intervention
(PCI), 34% medical treatment and 7.8% CABG. In the acute phase after PCI:
renal failure 11%( vs 6.3% after medical treatment), heart failure 7.3% (vs
6.3%), recurrence infarction 6.1% (vs: 0%). Mortality of 2.4% (vs: 0%).
At 6 month after PCI: renal failure 3.8% (vs: 0%), recurrent infarction
7.5% (vs 4,2%) and heart failure 6.3%(vs 8,3%). Mortality of 1.4%(vs: 0%).
The quality of life has improved in 45% after PCI, versus 12,5% after medical
treatment .
At 1 year after PCI: mortality 1,3% and recurrent infarction1. 3%. The
quality of life has improved in 53.2% versus 12.5% after medical treatment.
While a stationary quality of life is noted in 72.9% after medical treatment.
Angioplasty in elderly patients improves the quality of life, especially of
physical health, but with some cases of complications. While medical treat-
ment that maintained a steady state of quality of life with fewer complica-
tions.
